IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is an engineered analog of native IGF-1 that Echo Peptides supplies exclusively as a reference compound for laboratory and in-vitro research. The molecule carries an arginine substitution at position 3 together with a 13-amino-acid N-terminal extension, modifications that markedly reduce its affinity for IGF-binding proteins. In cell-culture systems this altered binding profile is the property researchers most often study, since it changes how the analog associates with the IGF-1 receptor relative to the unmodified peptide.

As a signaling reference standard, IGF-1 LR3 is used to interrogate receptor engagement and the downstream cascades classically associated with the IGF-1 receptor, including PI3K/Akt and MAPK pathway activity, in preclinical and in-vitro model systems.

Key research areas

  • Cell proliferation and differentiation — examining growth-signaling responses in cultured cell lines
  • Anabolic and IGF-1 receptor pathway signaling — profiling PI3K/Akt and MAPK cascade activity in vitro
  • IGF-binding-protein interaction studies — comparing the reduced-affinity analog against native IGF-1
  • Musculoskeletal and tissue-development models — investigating growth mechanisms in preclinical systems
  • Metabolic regulation research — studying nutrient and glucose-handling pathways at the cellular level

Specifications

  • Amount: 1mg per vial
  • Form: Lyophilized white powder
  • Solubility: Soluble in bacteriostatic water or research buffers for reconstitution
  • Storage: Refrigerate at 2–8°C; keep lyophilized powder sealed and protected from moisture
  • Quality: Third-party tested for identity and purity; a Certificate of Analysis is available on request

This product is intended for laboratory and in-vitro research use only. It is not for human or veterinary use, and not for diagnostic, therapeutic, or clinical applications.